Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Improved radioimmunotherapy of hematologic malignancies

Technical Report ·
OSTI ID:5514112
In the seven months which have elapsed since initial funding of this project, considerable progress has been made towards achieving the objectives of this research. These objectives include: to study the relative rates of metabolic degradation of radiolabeled monoclonal antibodies (mAbs) targeting tumor associated antigens; to examine the effects of lysomotropic amines (ammonium chloride, chloroquine, amantadine), carboxylic ionophores (monensin), and thionamides (propylthiouracil), on the retention of radiolabeled mAbs by tumor cells; to identify the subcellular site of radioimmunoconjugate degradation, and to quantify the sizes of the fragments generated by intracellular metabolism of radiolabeled mAbs; to examine the effects of lysomotropic agents on the quality of external gamma camera imaging and radiation dosimetry generated in tumor-bearing mice injected with radiolabeled mAbs; to examine the effects of lysomotropic agents on the radiotherapeutic efficacy of radiolabeled mAbs in murine tumors and human tumors xenografted to nude mice; and to compare the effects of lysomotropic agents on the degradation of radioimmunoconjugates made with different radionuclides and different conjugation methods.
Research Organization:
Washington Univ., Seattle, WA (USA). Medical Oncology Lab.
Sponsoring Organization:
DOE/ER
DOE Contract Number:
FG06-88ER60719
OSTI ID:
5514112
Report Number(s):
DOE/ER/60719-1; ON: DE89017444
Country of Publication:
United States
Language:
English